, Tracking Stock Market Picks
Enter Symbol:
Rating: NVDTF
Overweight $15

Novadaq Technologies Inc. (NASDAQ: NVDQ) rated to Overweight with price target $15 by First Analysis Sec

Thursday,  Oct 29, 2015  8:25 AM ET by Kristen Bailey

First Analysis Sec rated Novadaq
Technologies Inc. (NASDAQ: NVDQ) to Overweight with price target $15.

Novadaq Technologies Inc. (Novadaq) develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company?s imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. Novadaq develops and markets real-time fluorescence imaging technologies for use in the operating room. The company?s key markets include plastic reconstructive, gastrointestinal, cardiac and general surgery. The Company?s primary core technology platform, SPY Imaging provides anatomic and physiologic images during a variety of complex open and minimally invasive surgical (MIS) procedures. In January 2009, Novadaq announced its first alliance with Intuitive Surgical, Inc., to integrate SPY imaging into the da Vinci Surgical Robot.

First Analysis clients and partners can access the First Analysis research library on-line by clicking on the “Search research” link or entering a ticker (in the search box below) and hitting the return key. First Analysis Securities Corporation provides institutional investors with research on more than 100 publicly traded companies in its sectors of specialization. Our approach—a research focus that encompasses both private and public companies—leads to broad, deep understanding of our industries and companies. First Analysis is committed to long-term, life-cycle industry coverage. First Analysis Securities Corp. (FASC) is a registered broker/dealer with the FINRA and SIPC.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy